Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage II colon cancer.

ABSTRACT: Optimal selection of high-risk patients with stage II colon cancer is crucial to ensure clinical benefit of adjuvant chemotherapy. Here, we investigated the prognostic value of genomic intratumor heterogeneity and aneuploidy for disease recurrence. We combined targeted sequencing, SNP arrays, fluorescence in situ hybridization, and immunohistochemistry on a retrospective cohort of 84 untreated stage II colon cancer patients. We assessed the clonality of copy-number alterations (CNAs) and mutations, CD8⁺ lymphocyte infiltration, and their association with time to recurrence. Prognostic factors were included in machine learning analysis to evaluate their ability to predict individual relapse risk. Tumors from recurrent patients displayed a greater proportion of CNAs compared with

SUBMITTER: Lahoz S 

PROVIDER: S-EPMC9790656 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature